Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 2970-2988

  Brahmachari, Saurav ^a,b   Ge, Preston ^a,b   Lee, Su Hyun ^a   Kim, Donghoon ^a,c   Karuppagounder, Senthilkumar S ^a,b   Kumar, Manoj ^a,b   Mao, Xiaobo ^a,b   Shin, Joo Ho ^a,b   Lee, Yunjong ^a,b,d   Pletnikova, Olga ^a   Troncoso, Juan C ^a   Dawson, Valina L ^a,b   Dawson, Ted M ^a,b   Ko, Han Seok ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^c Diana Helis Henry Medical Research Foundation   (United States)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; BCR ABL PROTEIN; BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; UBIQUITIN; PHOSPHOTYROSINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BASAL AMYGDALA; BRAIN CORTEX; BRAIN TISSUE; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; LEWY BODY; LOCUS CERULEUS; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; ANIMAL; BRAIN; DEGENERATIVE DISEASE; DISEASE MODEL; FEMALE; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; MUTATION; NEURITE; NEUROPROTECTION; PHOSPHORYLATION; TRANSGENIC MOUSE;

AGED; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HEK293 CELLS; HUMANS; LEWY BODIES; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEURITES; NEURODEGENERATIVE DISEASES; NEUROPROTECTION; PARKINSON DISEASE; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTO-ONCOGENE PROTEINS C-ABL;

EID: 84983745648     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85456     Document Type: Article

References (63)

1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744-1754.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909.
3. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316.
4. Goedert M. α-Synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2(7):492-501.
5. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13-24.
6. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006;52(1):33-38.
7. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron. 2010;66(5):646-661.
8. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003;4(9):727-738.
9. Polymeropoulos MH, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-2047.
10. Zarranz JJ, et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-173.
11. Krüger R, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet. 1998;18(2):106-108.
12. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet. 2011;12:301-325.
13. Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord. 2013;28(1):61-70.
14. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011;10(12):1108-1118.
15. Deng H, Yuan L. Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev. 2014;15:161-176.
16. Fernagut PO, Chesselet MF. α-Synuclein and transgenic mouse models. Neurobiol Dis. 2004;17(2):123-130.
17. Lee Y, Dawson VL, Dawson TM. Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb Perspect Med. 2012;2(10):a009324.
18. Fujiwara H, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160-164.
19. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 2008;28(30):7687-7698.
20. Hodara R, et al. Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem. 2004;279(46):47746-47753.
21. Giasson BI, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290(5493):985-989.
22. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33-44.
23. Ko HS, et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A. 2010;107(38):16691-16696.
24. Imam SZ, et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci. 2011;31(1):157-163.
25. Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet. 2013;22(16):3315-3328.
26. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep. 2014;4:4874.
27. Lee MK, et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53- Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002;99(13):8968-8973.
28. Martin LJ, et al. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26(1):41-50.
29. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci. 2012;32(10):3301-3305.
30. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron. 2002;34(4):521-533.
31. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A. 1995;92(14):6522-6526.
32. Smith WW, et al. Synphilin-1 attenuates neuronal degeneration in the A53T α-synuclein transgenic mouse model. Hum Mol Genet. 2010;19(11):2087-2098.
33. Von Coelln R, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A. 2004;101(29):10744-10749.
34. von Coelln R, et al. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of α-synucleinopathy. J Neurosci. 2006;26(14):3685-3696.
35. Schwartzberg PL, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 1991;65(7):1165-1175.
36. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65(7):1153-1163.
37. Moresco EM, Donaldson S, Williamson A, Koleske AJ. Integrin-mediated dendrite branch maintenance requires Abelson (Abl) family kinases. J Neurosci. 2005;25(26):6105-6118.
38. Bétemps D, et al. α-Synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA. Acta Neuropathol Commun. 2014;2:29.
39. Cunnington R, Iansek R, Johnson KA, Bradshaw JL. Movement-related potentials in Parkinson's disease. Motor imagery and movement preparation. Brain. 1997;120 (pt 8):1339-1353.
40. Burré J, Sharma M, Südhof TC. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci. 2012;32(43):15227-15242.
41. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. α-Synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics. 2013;12(12):3543-3558.
42. Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev Neurosci. 2013;24(2):115-123.
43. Lue LF, et al. Biochemical increase in phosphor-ylated α-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012;22(6):745-756.
44. Wang Y, et al. Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med. 2012;4(121):121ra20.
45. Gao L, et al. Cerebrospinal fluid α-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci. 2015;125(9):645-654.
46. Mahul-Mellier AL, et al. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet. 2014;23(11):2858-2879.
47. Gaki GS, Papavassiliou AG. Oxidative stressinduced signaling pathways implicated in the pathogenesis of Parkinson's disease. Neuromolecular Med. 2014;16(2):217-230.
48. Imam SZ, et al. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One. 2013;8(5):e65129.
49. Dawson TM, Dawson VL. Parkin plays a role in sporadic Parkinson's disease. Neurodegener Dis. 2014;13(2-3):69-71.
50. Hebron ML, Lonskaya I, Moussa CE. Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance. Autophagy. 2013;9(8):1249-1250.
51. Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in α-synucleinopathy. J Clin Cell Immunol. 2014;5:259.
52. Wu R, et al. c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death. Cell Death Differ. 2016;23(3):542-552.
53. Tanabe A, Yamamura Y, Kasahara J, Morigaki R, Kaji R, Goto S. A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease. Front Cell Neurosci. 2014;8:50.
54. Manley PW, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.
55. Konig H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008;22(4):748-755.
56. Lee Y, et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci. 2013;16(10):1392-1400.
57. Smith WW, et al. α-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci. 2005;25(23):5544-5552.
58. Shin JH, et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell. 2011;144(5):689-702.
59. Dauer W, et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99(22):14524-14529.
60. Hunot S, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2004;101(2):665-670.
61. Luk KC, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338(6109):949-953.
62. Lane EL, Winkler C, Brundin P, Cenci MA. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis. 2006;22(2):334-345.
63. Griffin PR, MacCoss MJ, Eng JK, Blevins RA, Aaronson JS, Yates JR. Direct database searching with MALDI-PSD spectra of peptides. Rapid Commun Mass Spectrom. 1995;9(15):1546-1551.